Department of General Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Department of General Thoracic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Ann Thorac Surg. 2021 Jul;112(1):e53-e55. doi: 10.1016/j.athoracsur.2020.09.083. Epub 2020 Dec 26.
Although concurrent chemoradiotherapy (CRT) followed by consolidation immunotherapy considerably improves the duration of survival in patients with unresectable stage III non-small cell lung cancer (NSCLC), few data are available on the management of local relapse after therapy. We present a patient with initially unresectable NSCLC who underwent a right upper lobectomy with reconstruction of the bronchus and pulmonary artery after definitive CRT, followed by consolidation durvalumab. No postoperative complications occurred, and he was recurrence-free at the 10-month follow-up. Salvage surgery might be a viable option for local relapse of NSCLC treated with definitive CRT and durvalumab.
虽然同步放化疗（CRT）后序贯巩固免疫治疗可显著改善不可切除 III 期非小细胞肺癌（NSCLC）患者的生存时间，但关于治疗后局部复发的管理数据有限。我们报告了 1 例初始不可切除 NSCLC 患者，在根治性 CRT 后接受了右上肺叶切除术，同时重建了支气管和肺动脉，随后进行了巩固性 durvalumab 治疗。术后无并发症发生，10 个月随访时无复发。对于接受根治性 CRT 和 durvalumab 治疗后发生局部复发的 NSCLC，挽救性手术可能是一种可行的选择。
